Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biovitrum to acquire Kepivance and Stemgen from Amgen
The financial terms of the transaction include an upfront payment of approximately $130 million, consisting of $110 million in cash and ordinary shares of Biovitrum, representing a value
The financial terms of the transaction include an upfront payment of approximately $130 million, consisting of $110 million in cash and ordinary shares of Biovitrum, representing a value
Under the terms of the agreement, the two companies will work jointly to develop an application of OmniSonics’s OmniWave technology for the treatment of acute ischemic stroke. The
These generic versions of alendronate sodium tablets 5mg (base), 10mg (base), 35mg (base) and 70mg (base) are bio-equivalent to Fosamax tablets distributed by Merck & Co. These products
Albumax has been approved under code B4155 as an enteral product. The approval is significant in that it allows for Medicaid reimbursement of costs for eligible patients using
Prior to his promotion, Mr Zhou served as vice president of manufacturing overseeing several good manufacturing practice manufacturing plants. As executive vice president, Mr Zhou broadens his responsibilities
With the addition of its two new independent agencies – Philadelphia-based Midlantic Technologies Group and Long Island-based Inter-Med Technologies – Neuro Kinetics now has eight independent sales representative
In this role, Dr Skog will oversee the research program that underlies the company’s development of its blood-based diagnostics that can identify cancer-specific genetic mutations. Dr Skog is
Terms of the agreement call for the German Red Cross in the Baden-Wurttemberg–Hessen region (DRK Frankfurt) to invest both expertise and personnel in support of commercial system design,
Under the terms of the agreement, Unibioscreen will receive upfront, development and regulatory milestones payments up to $31 million, in addition to commercial milestone payments. The license grants
Lundbeck said that this is the first new drug application (NDA) submitted in the US by the company, and it follows the launch of Serdolect in Europe, South